AI May Help With MRI Interpretation During Prostate Cancer Detection

Commentary
Video

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

CancerNetwork® spoke with Wayne G. Brisbane, MD during Prostate Cancer Awareness Month 2023 about how implementing artificial intelligence (AI) into the clinical landscape may help in detecting prostate cancer more effectively in patients who need to undergo an MRI.

Brisbane, an assistant professor of urology at the University of California, Los Angeles (UCLA) Health, discussed his experiences with a machine learning algorithm called Unfold AI in patients with elevated prostate specific antigen (PSA) levels who need to proceed to an MRI, which his practice often employs in prostate cancer detection. He described how the AI program may be able to elucidate signs of disease in an MRI that are not typically perceptible to the human eye, thereby giving information on how best to manage the tumor.

Transcript:

AI is being used in prostate cancer in a couple of different ways, mostly on the diagnostic side. I use it in men who come in with an elevated PSA, which is our best and most reliable way to screen men for prostate cancer. If you have an elevated PSA—I tell men it’s like a thermometer for your prostate; it goes up for all kinds of reasons—maybe it’s something in the prostate that could just be size or some inflammation, but it could be prostate cancer. [Therefore], we need to figure out exactly what that is for men.

We’re using AI to interpret the MRIs. After a PSA elevation, oftentimes men will get an MRI or a biomarker [assessment]—in my [practice], we use MRI quite a bit. We will use the MRIs, and if it doesn’t look like there’s anything to the naked eye, we’ll have an AI go and take a second look at it. [From there] if there is a lesion on the MRI and we do a biopsy. We’re using a machine learning algorithm called Unfold AI that carefully predicts the location and extent of the tumor. We use that to help us perform treatments.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content